An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
Sponsor: Stealth BioTherapeutics Inc.
Listed as NCT02848313, this PHASE1 trial focuses on Age-Related Macular Degeneration and remains completed. Sponsored by Stealth BioTherapeutics Inc., it has been updated 12 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 7 earlier versions
-
Oct 2020 — Nov 2020 [monthly]
Completed PHASE1
-
Jun 2020 — Oct 2020 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Oct 2019 — Jun 2020 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Oct 2019 [monthly]
Active Not Recruiting PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Stealth BioTherapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .